• 1
    Ezaki H, Ebihara S, Fujimoto Y, et al. Analysis of thyroid carcinoma based on material registered in Japan during 1977–1986 with special preference to predominance of papillary type. Cancer. 1992; 70: 808814.
  • 2
    Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985; 42: 581588.
  • 3
    Santoro M, Carlomagno F, Hay ID, et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest. 1992; 89: 15171522.
  • 4
    Bongarzone I, Butti MG, Coronelli S, et al. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res. 1994; 54: 29792985.
  • 5
    Lam AK, Montone KT, Nolan KA, et al. Ret oncogene activation in papillary thyroid carcinoma: prevalence and implication on the histological parameters. Hum Pathol. 1998; 29: 565568.
  • 6
    Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res. 1998; 4: 287294.
  • 7
    Jhiang SM, Caruso DR, Gilmore E, et al. Detection of the PTC/retTPC oncogene in human thyroid cancers. Oncogene. 1992; 7: 13311337.
  • 8
    Nikiforova MN, Caudill CM, Biddinger P, Nikiforov YE. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol. 2002; 10: 1522.
  • 9
    Sugg SL, Ezzat S, Zheng L, et al. Oncogene profile of papillary thyroid carcinoma. Surgery. 1999; 125: 4652.
  • 10
    Zou MJ, Shi YF, Farid NR. Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from Saudi Arabia. Cancer. 1994; 73: 176180.
  • 11
    Chua EL, Wu WM, Tran KT, et al. Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia. J Clin Endocrinol Metab. 2000; 85: 27332739.
  • 12
    Lee CH, Hsu LS, Chi CW, et al. High frequency of rearrangement of the RET protooncogene (RET/PTC) in Chinese papillary thyroid carcinomas. J Clin Endocrinol Metab. 1998; 83: 16291632.
  • 13
    Namba H, Yamashita S, Pei HC, et al. Lack of PTC gene (ret proto-oncogene rearrangement) in human thyroid tumors. Endocrinol Jpn. 1991; 38: 627632.
  • 14
    Wajjwalku W, Nakamura S, Hasegawa Y, et al. Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas. Jpn J Cancer Res. 1992; 83: 671675.
  • 15
    Ishizuka Y, Kobayashi S, Ushijima T, et al. Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene. 1991; 6: 16671672.
  • 16
    Kitamura Y, Minobe K, Nakata T, et al. Ret/PTC3 is the most frequent form of gene rearrangement in papillary thyroid carcinomas in Japan. J Hum Genet. 1999; 44: 96102.
  • 17
    Motomura T, Nikiforov YE, Namba H, et al. ret rearrangements in Japanese pediatric and adult papillary thyroid cancers. Thyroid. 1998; 8: 485489.
  • 18
    Nikiforov YE, Rowland JM, Bove KE, et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997; 57: 16901694.
  • 19
    Rabes HM, Demidchik EP, Sidorow JD, et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res. 2000; 6: 10931103.
  • 20
    Fugazzola L, Pilotti S, Pinchera A, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res. 1995; 55: 56175620.
  • 21
    Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene. 1995; 11: 24592467.
  • 22
    Smida J, Salassidis K, Hieber L, et al. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int J Cancer. 1999; 80: 3238.
  • 23
    Thomas GA, Bunnell H, Cook HA, et al. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab. 1999; 84: 42324238.
  • 24
    Bounacer A, Wicker R, Caillou B, et al. High prevalence of activating ret proto-oncogene rearrangements, thyroid tumors from patients who had received external radiation. Oncogene. 1997; 15: 12631273.
  • 25
    Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002; 13: 316.
  • 26
    Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearrangement form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990; 60: 557563.
  • 27
    Santoro M, Dathan NA, Berlingieri MT, et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene. 1994; 9: 509516.
  • 28
    Hedinger C, Williams ED, Sobin LH. Histological classification of thyroid tumours. In: HedingerC, WilliamsED, SobinLH, editors. Histological typing of thyroid tumours. World Health Organization international histological classification of tumours, 2nd edition. Paris: Springer-Verlag, 1988: 318.
  • 29
    Kobayashi Y, Kawaoi A, Katoh R. Mutation of ras oncogene in di-isopropanolnitrosamine-induced rat thyroid carcinogenesis. Virchows Arch. 2002; 441: 289295.
  • 30
    Ishizuka Y, Ushijima T, Sugimura T, Nagao M. cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line. Biochem Biophys Res Commun. 1990; 168: 402408.
  • 31
    Fenton CL, Lukes Y, Nicholson D, et al. The ret/PTC mutations are common in sporadic papillary carcinoma of children and young adults. J Clin Endocrinol Metab. 2000; 85: 11701175.
  • 32
    Shi YF, Zou MJ, Schmidt H, et al. High rates of ras codon 61 mutation in thyroid tumors in an iodine-deficient area. Cancer Res. 1991; 51: 26902693.
  • 33
    Bongarzone I, Fugazzola L, Vigneri P, et al. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab. 1996; 81: 20062009.
  • 34
    Bongarzone I, Vigneri P, Mariani L, et al. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res. 1998; 4: 223228.
  • 35
    Sugg SL, Ezzat S, Rosen IB, et al. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab. 1998; 83: 41164122.
  • 36
    Eng C, Mulligan LM, Healey CS, et al. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res. 1996; 56: 21672170.
  • 37
    Williams GH, Rooney S, Thomas GA, Cummins G, Williams ED. RET activation in adult and childhood papillary thyroid carcinoma using a reverse transcriptase-n-polymerase chain reaction approach on archival-nested material. Br J Cancer. 1996; 74: 585589.
  • 38
    Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) Program 1973–1991. Cancer. 1997; 79: 564573.
  • 39
    Shah JP, Loree TR, Dharker D, et al. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg. 1992; 164: 658661.